Program
MEDI0618
A development code.
In AbbVie's pipeline, PAR-2
. Its studies are mostly in Chronic Pain · Migraine Disorders, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 20 open or running | phase 1since Nov 25, 2019 | Nov 25, 2019 | none ahead |
| AbbVie | 11 open or running | phase 2since Sep 16, 2024 | Sep 16, 2024 | Feb 2027phase 2 · NCT06602479 |
- Named in AbbVie’s own pipeline as
ABBV-2002
, phase 2, as of Jul 30, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 25, 2019First study: phase 1 study in Chronic PainNew to AstraZenecaAstraZeneca · NCT04198558 · 64 enrolled · Germany
- Dec 12, 2022Phase 1 study in Chronic PainAstraZeneca · NCT05714254 · 36 enrolled · Germany
- Sep 16, 2024AbbVie's first study: phase 2 study in Migraine DisordersNew to AbbVieAbbVie · NCT06602479 · 309 enrolled · United States, Czechia, Denmark and more
Ahead
- Feb 2027Primary completion: phase 2 study in Migraine DisordersAbbVie · NCT06602479
TargetBeta
“PAR-2”the company's pipeline, read by Claude · source
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06602479Migraine Disorders · United States, Czechia, Denmark and more | 2 | Active, not recruiting | AbbVie | Feb 2027 | 309 |
| NCT05714254Chronic Pain · Germany | 1 | Completed | AstraZeneca | Dec 12, 2023 | 36 |
| NCT04198558Chronic Pain · Germany | 1 | Completed | AstraZeneca | Feb 23, 2022 | 64 |
How it is read
Names in the registry
- “MEDI0618”, 3 entries
Codes read as this program: MEDI0618.
Conditions, from the studies’ own filings
- Chronic Pain, 2 studies
- Migraine Disorders, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.